OI
ALXN

Oakbrook Investments’s Alexion Pharmaceuticals ALXN Stock Holding History

Oakbrook Investments’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-4,450
Closed -$481K – 566
2019
Q4 		$481K Sell
4,450
-6,175
-58% -$660K 0.1% 343
2019
Q3 		$1.04M Sell
10,625
-1,600
-13% -$180K 0.07% 228
2019
Q2 		$1.6M Buy
+12,225
New +$1.58M 0.1% 167
2018
Q3 		– Sell
-17,980
Closed -$2.23M – 694
2018
Q2 		$2.23M Buy
+17,980
New +$2.1M 0.14% 114
2018
Q1 		– Sell
-16,850
Closed -$2.02M – 629
2017
Q4 		$2.02M Buy
16,850
+375
+2% +$45.7K 0.13% 120
2017
Q3 		$2.31M Sell
16,475
-275
-2% -$37.4K 0.15% 125
2017
Q2 		$2.04M Sell
16,750
-1,625
-9% -$189K 0.14% 132
2017
Q1 		$2.23M Buy
18,375
+8,250
+81% +$1.06M 0.15% 126
2016
Q4 		$1.24M Buy
+10,125
New +$1.24M 0.08% 192
2016
Q1 		– Sell
-12,739
Closed -$2.43M – 575
2015
Q4 		$2.43M Sell
12,739
-825
-6% -$144K 0.16% 119
2015
Q3 		$2.12M Hold
13,564
– – 0.14% 142
2015
Q2 		$2.45M Sell
13,564
-12,700
-48% -$2.19M 0.15% 138
2015
Q1 		$4.55M Buy
26,264
+11,425
+77% +$2.07M 0.25% 92
2014
Q4 		$2.75M Sell
14,839
-875
-6% -$162K 0.15% 140
2014
Q3 		$2.61M Sell
15,714
-15,725
-50% -$2.58M 0.14% 149
2014
Q2 		$4.91M Buy
31,439
+575
+2% +$90.8K 0.15% 159
2014
Q1 		$4.7M Sell
30,864
-38,450
-55% -$6.11M 0.15% 161
2013
Q4 		$9.21M Sell
69,314
-3,961
-5% -$475K 0.26% 107
2013
Q3 		$8.51M Buy
+73,275
New +$8.04M 0.25% 103

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Oakbrook Investments's ALXN Position: Q1 2020 in Review

Oakbrook Investments sold out of Alexion Pharmaceuticals (ALXN) in Q1 2020, closing a stake of 4,450 shares — an estimated $481K sold.

Oakbrook Investments first reported a position in ALXN in Q3 2013 and held it in 19 quarters. The position peaked at $9.21M in Q4 2013. 654 funds tracked by Wall St. Rank hold ALXN as of Q1 2020.

  • Oakbrook Investments reported no remaining Alexion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Oakbrook Investments sold 4,450 Alexion Pharmaceuticals shares in Q1 2020, an estimated $481K.
  • Oakbrook Investments first reported a position in Alexion Pharmaceuticals in Q3 2013 and held it in 19 quarters.
  • Oakbrook Investments's Alexion Pharmaceuticals position peaked at $9.21M in Q4 2013.
  • 654 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2020.

Based on Oakbrook Investments's 13F filing for Q1 2020, filed 22 Apr 2020.